Drugs Market Research Reports & Industry Analysis

The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.

Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.

A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.

Publications found: 10,876
Sort by:

Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) (Genetic Disorders) - Drugs in Development, 2021

US$ 2,000.00

Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) (Genetic Disorders) - Drugs in Development, 2021 SUMMARY Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) (Genetic Disorders) -...

April 2021 35 pages

Multiple Organ Failure (Multiple Organ Dysfunction Syndrome) (Other Diseases) - Drugs in Development, 2021

US$ 2,000.00

Multiple Organ Failure (Multiple Organ Dysfunction Syndrome) (Other Diseases) - Drugs in Development, 2021 SUMMARY Multiple Organ Failure (Multiple Organ Dysfunction Syndrome) (Other Diseases) - Drugs...

April 2021 35 pages

Muscarinic Acetylcholine Receptor M1 (CHRM1) - Drugs in Development, 2021

US$ 3,000.00

Muscarinic Acetylcholine Receptor M1 (CHRM1) - Drugs in Development, 2021 SUMMARY Muscarinic Acetylcholine Receptor M1 (CHRM1) - Drugs in Development, 2021 provides in depth analysis on Muscarinic Ace...

April 2021 75 pages

Muscarinic Acetylcholine Receptor M3 (CHRM3) - Drugs in Development, 2021

US$ 3,000.00

Muscarinic Acetylcholine Receptor M3 (CHRM3) - Drugs in Development, 2021 SUMMARY Muscarinic Acetylcholine Receptor M3 (CHRM3) - Drugs in Development, 2021 provides in depth analysis on Muscarinic Ace...

April 2021 65 pages

Muscle Atrophy (Musculoskeletal) - Drugs in Development, 2021

US$ 2,000.00

Muscle Atrophy (Musculoskeletal) - Drugs in Development, 2021 SUMMARY Muscle Atrophy (Musculoskeletal) - Drugs in Development, 2021 provides an overview of the Muscle Atrophy pipeline landscape. The r...

April 2021 30 pages

Muscle Injury (Musculoskeletal Disorders) - Drugs in Development, 2021

US$ 2,000.00

Muscle Injury (Musculoskeletal Disorders) - Drugs in Development, 2021 SUMMARY Muscle Injury (Musculoskeletal Disorders) - Drugs in Development, 2021 provides an overview of the Muscle Injury pipeline...

April 2021 30 pages

Muscle Invasive Bladder Cancer (MIBC) (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Muscle Invasive Bladder Cancer (MIBC) (Oncology) - Drugs in Development, 2021 SUMMARY Muscle Invasive Bladder Cancer (MIBC) (Oncology) - Drugs in Development, 2021 provides an overview of the Muscle I...

April 2021 75 pages

Muscle Spasm (Musculoskeletal) - Drugs in Development, 2021

US$ 2,000.00

Muscle Spasm (Musculoskeletal) - Drugs in Development, 2021 SUMMARY Muscle Spasm (Musculoskeletal) - Drugs in Development, 2021 provides an overview of the Muscle Spasm pipeline landscape. The report...

April 2021 30 pages

Muscle Spasticity (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Muscle Spasticity (Central Nervous System) - Drugs in Development, 2021 SUMMARY Muscle Spasticity (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Muscle Spasticity pi...

April 2021 50 pages

Muscle Wasting Disorders (Musculoskeletal Disorders) - Drugs in Development, 2021

US$ 2,000.00

Muscle Wasting Disorders (Musculoskeletal Disorders) - Drugs in Development, 2021 SUMMARY Muscle Wasting Disorders (Musculoskeletal Disorders) - Drugs in Development, 2021 provides an overview of the...

April 2021 30 pages

Musculoskeletal Pain (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Musculoskeletal Pain (Central Nervous System) - Drugs in Development, 2021 SUMMARY Musculoskeletal Pain (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Musculoskeleta...

April 2021 35 pages

Myalgia (Muscle Pain) (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Myalgia (Muscle Pain) (Central Nervous System) - Drugs in Development, 2021 SUMMARY Myalgia (Muscle Pain) (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Myalgia (Mus...

April 2021 30 pages

Mycobacterium avium Infections (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Mycobacterium avium Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Mycobacterium avium Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the My...

April 2021 35 pages

Mycobacterium Infections (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Mycobacterium Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Mycobacterium Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Mycobacterium...

April 2021 50 pages

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Drugs in Development, 2021

US$ 3,000.00

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Drugs in Development, 2021 SUMMARY Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secreto...

April 2021 30 pages

Mycobacterium Tuberculosis Infections (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Mycobacterium Tuberculosis Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Mycobacterium Tuberculosis Infections (Infectious Disease) - Drugs in Development, 2021 provides an over...

April 2021 40 pages

Mycobacterium tuberculosis Protein Ag85A - Drugs in Development, 2021

US$ 3,000.00

Mycobacterium tuberculosis Protein Ag85A - Drugs in Development, 2021 SUMMARY Mycobacterium tuberculosis Protein Ag85A - Drugs in Development, 2021 provides in depth analysis on Mycobacterium tubercul...

April 2021 30 pages

Mycosis Fungoides (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Mycosis Fungoides (Oncology) - Drugs in Development, 2021 SUMMARY Mycosis Fungoides (Oncology) - Drugs in Development, 2021 provides an overview of the Mycosis Fungoides pipeline landscape. The report...

April 2021 65 pages

Myelofibrosis (Hematological Disorders) - Drugs in Development, 2021

US$ 2,000.00

Myelofibrosis (Hematological Disorders) - Drugs in Development, 2021 SUMMARY Myelofibrosis (Hematological Disorders) - Drugs in Development, 2021 provides an overview of the Myelofibrosis pipeline lan...

April 2021 125 pages

Myeloperoxidase (MPO or EC 1.11.2.2) - Drugs in Development, 2021

US$ 3,000.00

Myeloperoxidase (MPO or EC 1.11.2.2) - Drugs in Development, 2021 SUMMARY Myeloperoxidase (MPO or EC 1.11.2.2) - Drugs in Development, 2021 provides in depth analysis on Myeloperoxidase (MPO or EC 1.1...

April 2021 30 pages

Myeloproliferative Disorders (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Myeloproliferative Disorders (Oncology) - Drugs in Development, 2021 SUMMARY Myeloproliferative Disorders (Oncology) - Drugs in Development, 2021 provides an overview of the Myeloproliferative Disorde...

April 2021 90 pages

Myopia (Ophthalmology) - Drugs in Development, 2021

US$ 2,000.00

Myopia (Ophthalmology) - Drugs in Development, 2021 SUMMARY Myopia (Ophthalmology) - Drugs in Development, 2021 provides an overview of the Myopia pipeline landscape. The report provides comprehensive...

April 2021 35 pages

Myotonic Dystrophy (Musculoskeletal) - Drugs in Development, 2021

US$ 2,000.00

Myotonic Dystrophy (Musculoskeletal) - Drugs in Development, 2021 SUMMARY Myotonic Dystrophy (Musculoskeletal) - Drugs in Development, 2021 provides an overview of the Myotonic Dystrophy pipeline land...

April 2021 75 pages

Myxoid Liposarcoma (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Myxoid Liposarcoma (Oncology) - Drugs in Development, 2021 SUMMARY Myxoid Liposarcoma (Oncology) - Drugs in Development, 2021 provides an overview of the Myxoid Liposarcoma pipeline landscape. The rep...

April 2021 35 pages

NAD+ ADP Ribosyltransferase (Poly Adenosine Diphosphate Ribose Polymerase or PARP or EC 2.4.2.30) - Drugs in Development, 2021

US$ 3,000.00

NAD+ ADP Ribosyltransferase (Poly Adenosine Diphosphate Ribose Polymerase or PARP or EC 2.4.2.30) - Drugs in Development, 2021 SUMMARY NAD+ ADP Ribosyltransferase (Poly Adenosine Diphosphate Ribose Po...

April 2021 65 pages

NADH Ubiquinone Oxidoreductase Chain 1 (NADH Dehydrogenase Subunit 1 or MT-ND1 or EC 7.1.1.2) - Drugs in Development, 2021

US$ 3,000.00

NADH Ubiquinone Oxidoreductase Chain 1 (NADH Dehydrogenase Subunit 1 or MT-ND1 or EC 7.1.1.2) - Drugs in Development, 2021 SUMMARY NADH Ubiquinone Oxidoreductase Chain 1 (NADH Dehydrogenase Subunit 1...

April 2021 30 pages

NADPH Oxidase (NOX or EC 1.6.3.1) - Drugs in Development, 2021

US$ 3,000.00

NADPH Oxidase (NOX or EC 1.6.3.1) - Drugs in Development, 2021 SUMMARY NADPH Oxidase (NOX or EC 1.6.3.1) - Drugs in Development, 2021 provides in depth analysis on NADPH Oxidase (NOX or EC 1.6.3.1) ta...

April 2021 45 pages

Na+/K+ Exchanging ATPase (Sodium Potassium ATPase or Sodium Potassium Pump or EC 7.2.2.13) - Drugs in Development, 2021

US$ 3,000.00

Na+/K+ Exchanging ATPase (Sodium Potassium ATPase or Sodium Potassium Pump or EC 7.2.2.13) - Drugs in Development, 2021 SUMMARY Na+/K+ Exchanging ATPase (Sodium Potassium ATPase or Sodium Potassium Pu...

April 2021 35 pages

Natural Killer Cell Lymphomas (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Natural Killer Cell Lymphomas (Oncology) - Drugs in Development, 2021 SUMMARY Natural Killer Cell Lymphomas (Oncology) - Drugs in Development, 2021 provides an overview of the Natural Killer Cell Lymp...

April 2021 100 pages

Nausea (Gastrointestinal) - Drugs in Development, 2021

US$ 2,000.00

Nausea (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Nausea (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Nausea pipeline landscape. The report provides compreh...

April 2021 40 pages

Necrotizing Enterocolitis (Gastrointestinal) - Drugs in Development, 2021

US$ 2,000.00

Necrotizing Enterocolitis (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Necrotizing Enterocolitis (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Necrotizing Ente...

April 2021 40 pages

Neisseria Gonorrhoeae Infections (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Neisseria Gonorrhoeae Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Neisseria Gonorrhoeae Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of th...

April 2021 35 pages

Neonatal Respiratory Distress Syndrome (Respiratory) - Drugs in Development, 2021

US$ 2,000.00

Neonatal Respiratory Distress Syndrome (Respiratory) - Drugs in Development, 2021 SUMMARY Neonatal Respiratory Distress Syndrome (Respiratory) - Drugs in Development, 2021 provides an overview of the...

April 2021 35 pages

Nerve Injury (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Nerve Injury (Central Nervous System) - Drugs in Development, 2021 SUMMARY Nerve Injury (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Nerve Injury pipeline landscap...

April 2021 30 pages

Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) (Genetic Disorders) - Drugs in Development, 2021

US$ 2,000.00

Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) (Genetic Disorders) - Drugs in Development, 2021 SUMMARY Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) (Genetic Disorders) - Dru...

April 2021 40 pages

Neuroendocrine Cancer (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Neuroendocrine Cancer (Oncology) - Drugs in Development, 2021 SUMMARY Neuroendocrine Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Neuroendocrine Cancer pipeline landscape...

April 2021 45 pages

Neuroendocrine Carcinoma (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Neuroendocrine Carcinoma (Oncology) - Drugs in Development, 2021 SUMMARY Neuroendocrine Carcinoma (Oncology) - Drugs in Development, 2021 provides an overview of the Neuroendocrine Carcinoma pipeline...

April 2021 40 pages

Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) (Oncology) - Drugs in Development, 2021 SUMMARY Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) (Oncology) - Drugs in Development, 2021 pr...

April 2021 55 pages

Neurogenic Locus Notch Homolog Protein 1 (Translocation Associated Notch Protein TAN 1 or NOTCH1) - Drugs in Development, 2021

US$ 3,000.00

Neurogenic Locus Notch Homolog Protein 1 (Translocation Associated Notch Protein TAN 1 or NOTCH1) - Drugs in Development, 2021 SUMMARY Neurogenic Locus Notch Homolog Protein 1 (Translocation Associate...

April 2021 35 pages

Neuroinflammation (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Neuroinflammation (Central Nervous System) - Drugs in Development, 2021 SUMMARY Neuroinflammation (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Neuroinflammation pi...

April 2021 90 pages

Neuromedin K Receptor (NK3 Receptor or Neurokinin B Receptor or Tachykinin Receptor 3 or NK3R or TACR3) - Drugs in Development, 2021

US$ 3,000.00

Neuromedin K Receptor (NK3 Receptor or Neurokinin B Receptor or Tachykinin Receptor 3 or NK3R or TACR3) - Drugs in Development, 2021 SUMMARY Neuromedin K Receptor (NK3 Receptor or Neurokinin B Recepto...

April 2021 30 pages

Neuromuscular Disorders (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Neuromuscular Disorders (Central Nervous System) - Drugs in Development, 2021 SUMMARY Neuromuscular Disorders (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Neuromus...

April 2021 55 pages

Neuronal Acetylcholine Receptor Subunit Alpha 3 (CHRNA3) - Drugs in Development, 2021

US$ 3,000.00

Neuronal Acetylcholine Receptor Subunit Alpha 3 (CHRNA3) - Drugs in Development, 2021 SUMMARY Neuronal Acetylcholine Receptor Subunit Alpha 3 (CHRNA3) - Drugs in Development, 2021 provides in depth an...

April 2021 30 pages

Neuronal Acetylcholine Receptor Subunit Beta 4 (CHRNB4) - Drugs in Development, 2021

US$ 3,000.00

Neuronal Acetylcholine Receptor Subunit Beta 4 (CHRNB4) - Drugs in Development, 2021 SUMMARY Neuronal Acetylcholine Receptor Subunit Beta 4 (CHRNB4) - Drugs in Development, 2021 provides in depth anal...

April 2021 30 pages

Neuropathic Pain (Neuralgia) (Central Nervous System) - Drugs in Development, 2021

US$ 2,500.00

Neuropathic Pain (Neuralgia) (Central Nervous System) - Drugs in Development, 2021 SUMMARY Neuropathic Pain (Neuralgia) (Central Nervous System) - Drugs in Development, 2021 provides an overview of th...

April 2021 325 pages

Neuropathy (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Neuropathy (Central Nervous System) - Drugs in Development, 2021 SUMMARY Neuropathy (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Neuropathy pipeline landscape. The...

April 2021 35 pages

Neuropilin 1 (Vascular Endothelial Cell Growth Factor 165 Receptor or CD304 or NRP1) - Drugs in Development, 2021

US$ 3,000.00

Neuropilin 1 (Vascular Endothelial Cell Growth Factor 165 Receptor or CD304 or NRP1) - Drugs in Development, 2021 SUMMARY Neuropilin 1 (Vascular Endothelial Cell Growth Factor 165 Receptor or CD304 or...

April 2021 30 pages

Neurotensin Receptor Type 1 (NTR1 or High Affinity Levocabastine Insensitive Neurotensin Receptor or NTRH or NTSR1) - Drugs in Development, 2021

US$ 3,000.00

Neurotensin Receptor Type 1 (NTR1 or High Affinity Levocabastine Insensitive Neurotensin Receptor or NTRH or NTSR1) - Drugs in Development, 2021 SUMMARY Neurotensin Receptor Type 1 (NTR1 or High Affin...

April 2021 30 pages

Nicotinamide N Methyltransferase (NNMT or EC 2.1.1.1) - Drugs in Development, 2021

US$ 3,000.00

Nicotinamide N Methyltransferase (NNMT or EC 2.1.1.1) - Drugs in Development, 2021 SUMMARY Nicotinamide N Methyltransferase (NNMT or EC 2.1.1.1) - Drugs in Development, 2021 provides in depth analysis...

April 2021 35 pages

Nicotine Addiction (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Nicotine Addiction (Central Nervous System) - Drugs in Development, 2021 SUMMARY Nicotine Addiction (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Nicotine Addiction...

April 2021 65 pages

Filters

Search

Publishers

1
450
353
174
29
4
837
409
36
27
2,279
77
19
16
2
21
1
16
1
9
9
2,264
5
4
31
6
142
1
17
15
248
651
91
1
373
26
34
724
1
2
16
6
4
84
36
3
4
2
7
15
53
16
26
83
11
32
8
2
17
106
27
19
4
7
3
324
15
1
23
86
24
28
44
296
17
18
2

Regions

131
40
38
37
37
35
32
23
13
10
10
9
9
8
8
8
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
6
6
6
6
6
6
5
5
5
5
4
4
3
3
3
3
3
91
12
354
30
6
6
4
4
4
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
2
2
39
6
4
3
3
3
1
1
3
7
9,529

Price

Date

Pages

Offers

9
1